Supplementary table B.2.                    Uni- and multivariate analyses of the prognostic value for predicting long-term grade ≥2 toxicity

|  | Univariate | | Multivariate | |
|---|---|---|---|---|
|  | HR (95% CI) | p value | HR (95% CI) | p value |
| **GU toxicity** | | | | |
| Age (≥ 70 year) | 1.22 (0.83-1.79) | 0.307 | | |
| Gleason Score (≥7) | 1.38 (0.89-2.14) | 0.155 | | |
| Risk-group (high-risk) | 0.86 (0.59-1.28) | 0.463 | | |
| Treatment group (including (base of) SVs) | 2.05 (1.12-3.74) | **0.017** | 2.77 (0.998-7.68) | 0.051 |
| Pre-treatment PSA (≥20 ng/mL) | 0.88 (0.54-1.42) | 0.593 | | |
| Neoadjuvant hormonal therapy (>6 months) | 1.45 (1.00-2.11) | 0.796 | | |
| Oral anticoagulants | 1.47 (0.85-2.54) | 0.169 | | |
| Pelvic surgery | 1.89 (1.30-2.76) | **0.001** | 1.92 (1.14-3.24) | **0.014** |
| Baseline symptoms of GU  toxicity (≥ grade 1) | 3.43 (1.90-6.19) | **<0.001** | 3.16 (1.75-5.73) | **<0.001** |
| | | | | |
| **GI toxicity** | | | | |
| Age (≥ 70 year) | 1.42 (0.81-2.51) | 0.226 | | |
| Gleason Score (≥7) | 2.05 (1.00-4.20) | **0.050** | 4.04 (1.22 - 13.36) | **0.022** |
| Risk-group (high-risk) | 1.49 (0.80-2.79) | 0.212 | | |
| Treatment group (including (base of) SVs) | 2.12 (0.84-5.34) | 0.110 | | |
| Pre-treatment PSA (≥20 ng/mL) | 1.49 (0.81-2.75) | 0.199 | | |
| Neoadjuvant hormonal therapy (>6 months) | 1.38 (0.61-3.13) | 0.436 | | |
| Oral anticoagulants | 1.46 (0.66-3.24) | 0.354 | | |
| Pelvic surgery | 1.32 (0.77-2.27) | 0.310 | | |
| Baseline symptoms of GU  toxicity (≥ grade 1) | 2.87 (1.18-7.02) | **0.021** | 3.34 (1.36-8.21) | **0.009** |

Abbreviations: GU = genitourinary; GI = gastrointestinal; SV = seminal vesicles; HR = hazard ratio; CI = confidence interval